Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Feasibility Study of Cholesterol Metabolism Reprogramming (Evolocumab, Atorvastatin and Ezetimibe) in Combination With the Standard of Care in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma

NCT04862260 is registered in ClinicalTrials.gov with CHU de Quebec-Universite Laval as lead sponsor.

NCT NCT04862260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04862260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Feasibility Study of Cholesterol Metabolism Reprogramming (Evolocumab, Atorvastatin and Ezetimibe) in Combination With the Standard of Care in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Lead sponsor
CHU de Quebec-Universite Laval
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 4, 2021
Completion date
December 31, 2026
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer, pancreas cancer, pancreatic cancer, pancreatic ductal adenocarcinoma